Compounds > triazoles
Page last updated: 2024-08-24

triazoles and Metabolic Diseases

triazoles has been researched along with Metabolic Diseases in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ai, Y; Guo, D; Li, Y; Obianom, ON; Sakamuru, S; Shu, Y; Xia, M; Xue, F; Yang, H; Yang, W1
Chang, E; Chowdhury, S; Dales, NA; Fu, J; Jia, Q; Khakh, K; Kwan, R; McLaren, DG; Pokrovskaia, N; Radomski, CC; Ratkay, LG; Sun, S; Winther, MD; Zhang, Z1
Aguilera-Lizarraga, J; Blanco, JR; Oteo, JA; Pérez-Martínez, L; Pérez-Matute, P1
Degraffenreid, M; He, X; Jaen, JC; Labelle, M; Liu, J; Meininger, D; Powers, JP; Shan, B; Sudom, A; Sun, D; Tu, H; Ursu, S; Walker, NP; Wang, Z; Xu, H; Yamamoto, H; Yan, X1

Other Studies

4 other study(ies) available for triazoles and Metabolic Diseases

ArticleYear
Triazole-Based Inhibitors of the Wnt/β-Catenin Signaling Pathway Improve Glucose and Lipid Metabolisms in Diet-Induced Obese Mice.
    Journal of medicinal chemistry, 2019, 01-24, Volume: 62, Issue:2

    Topics: Animals; beta Catenin; Diet, High-Fat; Glucose; Glucose Tolerance Test; HEK293 Cells; Hepatocytes; Humans; Lipid Metabolism; Lithium Chloride; Metabolic Diseases; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Structure-Activity Relationship; Triazoles; Wnt Signaling Pathway

2019
Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors.
    Bioorganic & medicinal chemistry, 2015, Feb-01, Volume: 23, Issue:3

    Topics: Animals; Drug Discovery; Hep G2 Cells; Humans; Lipid Metabolism; Metabolic Diseases; Mice; Rats; Rats, Inbred Lew; Stearoyl-CoA Desaturase; Structure-Activity Relationship; Triazoles

2015
Maraviroc modifies gut microbiota composition in a mouse model of obesity: a plausible therapeutic option to prevent metabolic disorders in HIV-infected patients.
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2015, Volume: 28, Issue:4

    Topics: Animals; Bacterial Translocation; Bacteroidetes; CCR5 Receptor Antagonists; Cecum; Cyclohexanes; Diet, High-Fat; Drug Evaluation, Preclinical; Firmicutes; HIV Fusion Inhibitors; HIV Infections; Humans; Insulin Resistance; Male; Maraviroc; Metabolic Diseases; Mice; Mice, Inbred C57BL; Microbiota; Non-alcoholic Fatty Liver Disease; Obesity; Proteobacteria; Random Allocation; Species Specificity; Triazoles; Weight Gain

2015
Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
    Bioorganic & medicinal chemistry, 2008, Oct-01, Volume: 16, Issue:19

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Amino Acid Sequence; Binding Sites; Biological Assay; Catalysis; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Kinetics; Metabolic Diseases; Molecular Sequence Data; NADP; Structure-Activity Relationship; Sulfonamides; Triazoles

2008